Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

Ziprasidone in adolescents with schizophrenia: results from a placebo-controlled efficacy and long-term open-extension study.

Findling RL, Cavuş I, Pappadopulos E, Vanderburg DG, Schwartz JH, Gundapaneni BK, DelBello MP.

J Child Adolesc Psychopharmacol. 2013 Oct;23(8):531-44. doi: 10.1089/cap.2012.0068. Epub 2013 Oct 10.

2.

Efficacy, long-term safety, and tolerability of ziprasidone in children and adolescents with bipolar disorder.

Findling RL, Cavuş I, Pappadopulos E, Vanderburg DG, Schwartz JH, Gundapaneni BK, DelBello MP.

J Child Adolesc Psychopharmacol. 2013 Oct;23(8):545-57. doi: 10.1089/cap.2012.0029. Epub 2013 Oct 10.

3.

Safety and Efficacy from an 8 Week Double-Blind Trial and a 26 Week Open-Label Extension of Asenapine in Adolescents with Schizophrenia.

Findling RL, Landbloom RP, Mackle M, Pallozzi W, Braat S, Hundt C, Wamboldt MZ, Mathews M.

J Child Adolesc Psychopharmacol. 2015 Jun;25(5):384-96. doi: 10.1089/cap.2015.0027.

5.

A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia.

Findling RL, Robb A, Nyilas M, Forbes RA, Jin N, Ivanova S, Marcus R, McQuade RD, Iwamoto T, Carson WH.

Am J Psychiatry. 2008 Nov;165(11):1432-41. doi: 10.1176/appi.ajp.2008.07061035. Epub 2008 Sep 2.

PMID:
18765484
6.
7.

Tolerability of oral ziprasidone in children and adolescents with bipolar mania, schizophrenia, or schizoaffective disorder.

DelBello MP, Versavel M, Ice K, Keller D, Miceli J.

J Child Adolesc Psychopharmacol. 2008 Oct;18(5):491-9. doi: 10.1089/cap.2008.008.

PMID:
18928413
8.

Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial.

Keck PE Jr, Versiani M, Potkin S, West SA, Giller E, Ice K; Ziprasidone in Mania Study Group.

Am J Psychiatry. 2003 Apr;160(4):741-8.

PMID:
12668364
9.

Ziprasidone in treatment-resistant schizophrenia: a 52-week, open-label continuation study.

Loebel AD, Khanna S, Rajadhyaksha S, Siu CO, Giller E, Potkin SG.

J Clin Psychiatry. 2007 Sep;68(9):1333-8.

PMID:
17915970
10.

Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia.

Cutler AJ, Kalali AH, Weiden PJ, Hamilton J, Wolfgang CD.

J Clin Psychopharmacol. 2008 Apr;28(2 Suppl 1):S20-8. doi: 10.1097/JCP.0b013e318169d4ce.

PMID:
18334909
11.

Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double- blind, placebo-controlled, multicenter studies.

Keck PE Jr, Reeves KR, Harrigan EP; Ziprasidone Study Group.

J Clin Psychopharmacol. 2001 Feb;21(1):27-35.

PMID:
11199944
12.

[Switching patients with schizophrenia to ziprasidone from conventional or other atypical antipsychotics].

Bartkó G, Trixler M, Bitter I, Degrell I, Füredi J, Faludi G; Ziprasidonra Váltást Vizsgáló Munkacsoport.

Neuropsychopharmacol Hung. 2006 Dec;8(4):201-9. Hungarian.

PMID:
17211055
13.

Ziprasidone and the corrected QT interval: a comprehensive summary of clinical data.

Camm AJ, Karayal ON, Meltzer H, Kolluri S, O'Gorman C, Miceli J, Tensfeldt T, Kane JM.

CNS Drugs. 2012 Apr 1;26(4):351-65. doi: 10.2165/11599010-000000000-00000.

PMID:
22452529
14.

Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial.

Keck P Jr, Buffenstein A, Ferguson J, Feighner J, Jaffe W, Harrigan EP, Morrissey MR.

Psychopharmacology (Berl). 1998 Nov;140(2):173-84.

PMID:
9860108
15.

Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.

Citrome L, Meng X, Hochfeld M, Stahl SM.

Hum Psychopharmacol. 2012 Jan;27(1):24-32. doi: 10.1002/hup.1254. Epub 2011 Dec 7.

PMID:
22161738
16.

Efficacy and safety of ziprasidone in the treatment of first-episode psychosis: an 8-week, open-label, multicenter trial.

Zhao T, Park TW, Yang JC, Huang GB, Kim MG, Lee KH, Chung YC.

Int Clin Psychopharmacol. 2012 Jul;27(4):184-90. doi: 10.1097/YIC.0b013e3283528d22.

PMID:
22426471
17.

A comparison of ziprasidone and risperidone in the long-term treatment of schizophrenia: a 44-week, double-blind, continuation study.

Addington DE, Labelle A, Kulkarni J, Johnson G, Loebel A, Mandel FS.

Can J Psychiatry. 2009 Jan;54(1):46-54.

PMID:
19175979
18.

Efficacy and safety of quetiapine in adolescents with schizophrenia investigated in a 6-week, double-blind, placebo-controlled trial.

Findling RL, McKenna K, Earley WR, Stankowski J, Pathak S.

J Child Adolesc Psychopharmacol. 2012 Oct;22(5):327-42. doi: 10.1089/cap.2011.0092.

PMID:
23083020
19.

Ziprasidone in Black patients with schizophrenia: analysis of four short-term, double-blind studies.

Lawson WB, Herman BK, Loebel A, Lazariciu I, Malik M.

CNS Spectr. 2009 Sep;14(9):478-86.

PMID:
19890230
20.

Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia.

Breier A, Berg PH, Thakore JH, Naber D, Gattaz WF, Cavazzoni P, Walker DJ, Roychowdhury SM, Kane JM.

Am J Psychiatry. 2005 Oct;162(10):1879-87.

PMID:
16199834
Items per page

Supplemental Content

Write to the Help Desk